TISIDB

Summary
Symbol	TTPA
Name	tocopherol (alpha) transfer protein
Aliases	AVED; ataxia (Friedreich-like) with vitamin E deficiency; alphaTTP; alpha-TTP; tocopherol (alpha) transfer p ......
Chromosomal Location	8q12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm
Domain	PF00650 CRAL/TRIO domain PF03765 CRAL/TRIO
Function	Binds alpha-tocopherol, enhances its transfer between separate membranes, and stimulates its release from liver cells (PubMed:7887897). Binds both phosphatidylinol 3,4-bisphosphate and phosphatidylinol 4,5-bisphosphate; the resulting conformation change is important for the release of the bound alpha-tocopherol (By similarity).

> Gene Ontology [ TOP ]
Biological Process	GO:0001701 in utero embryonic development GO:0001890 placenta development GO:0001892 embryonic placenta development GO:0006766 vitamin metabolic process GO:0006775 fat-soluble vitamin metabolic process GO:0006885 regulation of pH GO:0007584 response to nutrient GO:0009268 response to pH GO:0009636 response to toxic substance GO:0009991 response to extracellular stimulus GO:0010721 negative regulation of cell development GO:0030004 cellular monovalent inorganic cation homeostasis GO:0030641 regulation of cellular pH GO:0031667 response to nutrient levels GO:0042360 vitamin E metabolic process GO:0045851 pH reduction GO:0046909 intermembrane transport GO:0048568 embryonic organ development GO:0048608 reproductive structure development GO:0051180 vitamin transport GO:0051452 intracellular pH reduction GO:0051453 regulation of intracellular pH GO:0055067 monovalent inorganic cation homeostasis GO:0060856 establishment of blood-brain barrier GO:0061458 reproductive system development GO:0090210 regulation of establishment of blood-brain barrier GO:0090212 negative regulation of establishment of blood-brain barrier GO:1901615 organic hydroxy compound metabolic process
Molecular Function	GO:0005543 phospholipid binding GO:0005546 phosphatidylinositol-4,5-bisphosphate binding GO:0008431 vitamin E binding GO:0019842 vitamin binding GO:0035091 phosphatidylinositol binding GO:0043168 anion binding GO:0043325 phosphatidylinositol-3,4-bisphosphate binding GO:1901981 phosphatidylinositol phosphate binding GO:1902936 phosphatidylinositol bisphosphate binding
Cellular Component	GO:0005770 late endosome

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	TTPA
Name	tocopherol (alpha) transfer protein
Aliases	AVED; ataxia (Friedreich-like) with vitamin E deficiency; alphaTTP; alpha-TTP; tocopherol (alpha) transfer p ......
Chromosomal Location	8q12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between TTPA and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	TTPA
Name	tocopherol (alpha) transfer protein
Aliases	AVED; ataxia (Friedreich-like) with vitamin E deficiency; alphaTTP; alpha-TTP; tocopherol (alpha) transfer p ......
Chromosomal Location	8q12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of TTPA in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	TTPA
Name	tocopherol (alpha) transfer protein
Aliases	AVED; ataxia (Friedreich-like) with vitamin E deficiency; alphaTTP; alpha-TTP; tocopherol (alpha) transfer p ......
Chromosomal Location	8q12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of TTPA in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.384	0.424
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.363	0.64
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.939	0.159
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	1.096	0.0614
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	1.112	0.288
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	1.07	0.352
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.385	0.707
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.217	0.881
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.919	0.546
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.546	0.528
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.381	0.742
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.735	0.0301

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of TTPA in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	7.1	-7.1	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	TTPA
Name	tocopherol (alpha) transfer protein
Aliases	AVED; ataxia (Friedreich-like) with vitamin E deficiency; alphaTTP; alpha-TTP; tocopherol (alpha) transfer p ......
Chromosomal Location	8q12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TTPA. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	TTPA
Name	tocopherol (alpha) transfer protein
Aliases	AVED; ataxia (Friedreich-like) with vitamin E deficiency; alphaTTP; alpha-TTP; tocopherol (alpha) transfer p ......
Chromosomal Location	8q12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TTPA. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TTPA. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	TTPA
Name	tocopherol (alpha) transfer protein
Aliases	AVED; ataxia (Friedreich-like) with vitamin E deficiency; alphaTTP; alpha-TTP; tocopherol (alpha) transfer p ......
Chromosomal Location	8q12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TTPA. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	TTPA
Name	tocopherol (alpha) transfer protein
Aliases	AVED; ataxia (Friedreich-like) with vitamin E deficiency; alphaTTP; alpha-TTP; tocopherol (alpha) transfer p ......
Chromosomal Location	8q12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of TTPA expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	TTPA
Name	tocopherol (alpha) transfer protein
Aliases	AVED; ataxia (Friedreich-like) with vitamin E deficiency; alphaTTP; alpha-TTP; tocopherol (alpha) transfer p ......
Chromosomal Location	8q12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between TTPA and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	TTPA
Name	tocopherol (alpha) transfer protein
Aliases	AVED; ataxia (Friedreich-like) with vitamin E deficiency; alphaTTP; alpha-TTP; tocopherol (alpha) transfer p ......
Chromosomal Location	8q12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting TTPA collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse TTPA